A Mild Risk of Neonatal Hyperthyroidism Follows Radioactive Iodine Therapy for Graves’ Disease Prior to Pregnancy | oneGRAVESvoice
Global Search
Global Search

Trusted Resources: Evidence & Education

Scientific literature and patient education texts

Back to Evidence & Education / Patient Education

A Mild Risk of Neonatal Hyperthyroidism Follows Radioactive Iodine Therapy for Graves’ Disease Prior to Pregnancy

key information

source: Clinical Thyroidology

year: 2019

summary/abstract:

Graves’ disease is an autoimmune condition and the most common cause of hyperthyroidism in women of childbearing age. It is caused by the patient making an antibody called TRAB (TSH Receptor Antibody) that attacks and turns on the thyroid, making it overactive. TRAB is detectable in the blood of most patients with Graves’ disease. TRAB can pass through to the baby and cause hyperthyroidism after delivery in mothers with Graves’ disease. This is called neonatal Graves’ disease. This is a risk for all babies that are born to mothers with Graves’ disease.

TRAB tends to decrease with treatment of Graves’ disease with anti-thyroid medications and, if it goes away or decreases low enough, the Graves’ disease goes into remission. TRAB also tends to decrease years after surgery. However, the amount of TRAB rises for several months after radioactive iodine therapy, but this effect may last longer in some individuals. This is likely due to the effect of the destruction of the thyroid by the radioactive iodine therapy. It is unknown if this increase in TRAB would have any effect on the thyroid function of babies or newborns of mother that have been previously treated with radioactive iodine. The goal of this study is to assess the risk of hyperthyroidism in newborns of mothers who were treated with radioactive iodine within 2 years before their pregnancy.

 

read more

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Powered by

Brought to you by

Supported through an independent
educational grant by

© 2022 rareLife solutions Inc.